参考文献 References
[1] GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 published correction appears in Lancet. 2023 Sep30;402(10408):1132.
[2] Xu Y, Lu J, Li M, et al. Diabetes in China part 1: epidemiology and risk factors. Lancet Public Health. 2024;9(12):e1089-e1097.
[3] Meng L, Lu Y, Wang X, et al. NPRC deletion attenuates cardiac fibrosis in diabetic mice by activating PKA/PKG and inhibiting TGF-β1/Smad pathways. Sci Adv. 2023;9(31): eadd4222.
[4] Ritchie RH, Abel ED. Basic Mechanisms of Diabetic Heart Disease. Circ Res. 2020;126(11):1501-1525.
[5] 樊静珊.阿托伐他汀对2型糖尿病大鼠心肌RhoA/ROCK信号通路和纤维化的影响[D].河北医科大学,2017.
[6] 高嘉梦,胡兵,申锷.心肌成纤维细胞转分化与糖尿病心肌病的研究进展[J].中华心血管病杂志,2020,48(10):885-889.
[7] 张毅,李妍菲.糖尿病心肌纤维化研究进展[J].湖北科技学院学报(医学版),2020,34(01):70-75.
[8] 丁小艳,吕丽丽,翟满满,等.糖尿病心肌病发病机制和治疗策略的研究进展[J].中国糖尿病杂志,2024,32(09):710-714.
[9] Xu, X., et al. (2020). "Metformin improves cardiac function in a mouse model of diabetic cardiomyopathy by enhancing autophagy." *Cardiovascular Diabetology*, 19(1), 1-14.
[10] Wang, Y., et al. (2019). "Metformin attenuates cardiac fibrosis in diabetic cardiomyopathy by inhibiting the TGF-β1/Smad3 signaling pathway." *Journal of Cellular Physiology*, 234(6), 8836-8845.
[11] Zhou, G., et al. (2001). "Role of AMP-activated protein kinase in mechanism of metformin action." *Journal of Clinical Investigation*, 108(8), 1167-1174.
[12] Madiraju, A. K., et al. (2014). "Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase." *Nature*, 510(7506), 542-546.
[13] Wang Z, Huang L, Han L, et al. The protective effect of sodium-glucose cotransporter-2 inhibitor on left ventricular global longitudinal strain in patients with type 2 diabetes mellitus according to disease duration. Sci Rep. 2025;15(1):5111.
[14] 林浩,袁得强,陈飞,等.SGLT2抑制剂在冠心病中的作用机制的研究进展[J].同济大学学报(医学版),2023,44(06):925-932.
[15] 李远翥,罗素新,黄毕.钠-葡萄糖协同转运蛋白2抑制剂对射血分数保留型心力衰竭的治疗进展[J].中国心血管病研究,2023,21(08):757-762.
[16] 李兴红,金春娜.新型降糖药物SGLT2抑制剂和GLP-1受体激动剂的心血管获益研究进展[J].心电与循环,2024, 43(05):524-529.
[17] 王凤梅,王波,宫志华,等.SGLT2抑制剂在心力衰竭治疗中的研究进展[J].临床误诊误治,2024,37(21):96-100.
[18] Marso, S. P., et al. (2016). "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes." *New England Journal of Medicine*, 375(4), 311-322.
[19] 王静,胡天晓.胰高血糖素样肽-1受体激动剂心血管获益研究进展[J].浙江医学,2024,46(21):2241-2244+2259.
[20] Havranek B, Loh R, Torre B, Redfield R, Halegoua-DeMarzio D. Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes. Sci Rep. 2025;15(1):4947.
[21] Westermeier F, Fisman EZ. Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges. Cardiovasc Diabetol. 2025;24(1):44.
[22] 周子默,周驰,杨雅元,等.心肌纤维化的发病及治疗研究进展[J].湖北科技学院学报(医学版),2022,36(05):452-456.
[23] 马艳红,陈冰,彭娇娇,等.ACE/ACE2失衡参与糖尿病心肌纤维化的形成[J].徐州医科大学学报,2021,41(06):430-436.
[24] Oliveira-Junior SA, Martinez PF, Guizoni DM, et al. AT1 receptor blockade attenuates insulin resistance and myocardial remodeling in rats with diet-induced obesity. PLoS One. 2014;9(1):e86447.
[25] Hori Y, Touei D, Saitoh R, et al. The Aldosterone Receptor Antagonist Eplerenone Inhibits Isoproterenol-Induced Collagen-I and 11β-HSD1 Expression in Rat Cardiac Fibroblasts and the Left Ventricle. Biol Pharm Bull.2017;40(10):1716-1723.
[26] Wang L, Cai Y, Jian L, et al. Impact of peroxisome proliferator-activated receptor- α on diabetic cardiomyopathy [J]. Cardiovasc Diabetol, 2021, 20(1):2.
[27] Wang X, Zhu XX, Jiao SY, et al. Cardiomyocyte peroxisome proliferator- activated receptor alpha is essential for energy metabolism and extracellular matrix homeostasis during pressure verload- induced cardiac remodeling[J]. Acta Pharmacol Sin, 2022, 43(5):1231-1242.
[28] 王秋丽,张瑞英.PPARα在心血管疾病中作用机制的研究进展[J].临床与病理杂志,2022,42(02):449-454.
[29] 吴晨方.PPAR-α/γ激动剂对代谢综合征心室重构的保护机制研究[D].中南大学,2014.
[30] 李真真,白杨,黄婷.非诺贝特联合胰岛素治疗2型糖尿病合并非酒精性脂肪性肝病患者疗效观察[J].肝脏,2022, 27(01): 103-105+122.
[31] Goumans MJ, Ten Dijke P. TGF-β Signaling in Control of Cardiovascular Function. Cold Spring Harb Perspect Biol. 2018;10(2):a022210.
[32] 马定虎,周宗涛,李政,等.ZLY18通过抑制TGF-β1/Smads通路改善血管紧张素Ⅱ诱导的心肌纤维化[J].中国药理学通报,2023,39(02):229-238.
[33] Peng J, Yang K, Tian H, et al. The mechanisms of Qizhu Tangshen formula in the treatment of diabetic kidney disease: Network pharmacology, machine learning, molecular docking and experimental assessment. Phytomedicine. 2023;108: 154525.
[34] 邱羽菲,史嘉翊,宋旭东,等.心肌纤维化的发生机制及治疗研究进展[J].心脏杂志,2021,33(05):553-557.
[35] Dastani M, Rahimi HR, Askari VR, et al. Three months of combination therapy with nano-curcumin reduces the inflammation and lipoprotein (a) in type 2 diabetic patients with mild to moderate coronary artery disease: Evidence of a randomized, double-blinded, placebo-controlled clinical trial. Biofactors. 2023;49(1):108-118.
[36] Jiang C, Li D, Chen L, et al. Quercetin ameliorated cardiac injury via reducing inflammatory actions and the glycerophospholipid metabolism dysregulation in a diabetic cardiomyopathy mouse model. Food Funct. 2022;13(14): 7847-7856.
[37] 李继舟,李宏伟,汤胜宇,等.金钗石斛多糖调节Plin5介导心肌细胞脂肪酸β氧化改善糖尿病大鼠心肌损伤[J].昆明医科大学学报,2024,45(10):8-16.